Showing 6791-6800 of 8649 results for "".
- Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbanceshttps://modernod.com/news/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances/2478713/Ocuphire Pharma announced the initiation of patient recruitment and screening in late December for its LYNX-1 phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances (NVD) at multiple sites in the US. NVD, also known as dim light vision disturban
- UK Officials Defend Contingency Plan to Mix COVID-19 Vaccines in Rare Caseshttps://modernod.com/news/uk-officials-defend-contingency-plan-to-mix-covid-19-vaccines-in-rare-cases/2478710/According to a guidance update on December 31, the UK government will allow people to be given doses of different COVID-19 vaccines under certain circumstances, despite a lack of evidence about the extent of immunity offered by such mixing. The issue has sparked criticism after a report in Th
- VSY Biotechnology Introduces Protectalon DUO OVD Kithttps://modernod.com/news/vsy-biotechnology-introduces-protectalon-duo-ovd-kit/2478673/VSY Biotechnology has launched Protectalon Duo, which aims to meet OVD needs at different stages of cataract surgery with a single kit. The dual pack contains high filling volume of one unit cohesive (14 mg/mL, 1.1 mL) and one unit dispersive (30 mg/ml, 1.1 ml). “NaHA-based OVDs prov
- Microsoft Rolls Out COVID-19 Vaccine Management Platform as Nationwide Distribution Gets Underwayhttps://modernod.com/news/microsoft-rolls-out-covid-19-vaccine-management-platform-as-nationwide-distribution-gets-underway/2478663/As the first U.S. healthcare workers begin to receive COVID-19 vaccines, Microsoft has launched a vaccine management platform for both government and health care customers, according to a Fierce Healthcare
- Zeiss Acquires Majority Stake in Arivis, Expands Imaging Technology Capabilitieshttps://modernod.com/news/zeiss-acquires-majority-stake-in-arivis-expands-imaging-technology-capabilities/2478629/
- Market Scope: Cornea Products Market to Grow an Estimated 6.1 Percent Through 2025https://modernod.com/news/market-scope-cornea-products-market-to-grow-an-estimated-6-1-percent-through-2025/2478618/Expanding use of products to treat many corneal diseases will increase the role of devices and surgery in the cornea treatment landscape, according to Market Scope. Over 1 billion people are affected by 50 corneal diseases that cause cornea impairment, including corneal ectasias, dystrophies, ker
- Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Material Recycled Through One By One Recycling Programhttps://modernod.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016. The program, made possible through a collaboration with TerraCycle, a leader in the collection and repurposing
- Zeiss Introduces Video Laryngoscopehttps://modernod.com/news/zeiss-introduces-video-laryngoscope/2478531/With the outbreak of the COVID-19 crisis earlier this year, the Medical Technology segment of Zeiss focused on he
- Leiters and EyeConnect International Announce Corporate Partnershiphttps://modernod.com/news/leiters-and-eyeconnect-international-announce-corporate-partnership/2478520/Leiters, a provider of ophthalmic compounded sterile preparations and pharmacy services, has entered into a partnership with EyeConnect International (ECI) in support of their newly created digital ophthalmic clinical networking platform. Terms of the deal were not disclosed. EyeCon
- Llama ‘Nanobodies’ May Yield COVID-19 Treatment, Pitt Scientists Sayhttps://modernod.com/news/llama-nanobodies-may-yield-covid-19-treatment-pitt-scientists-say/2478500/Could Wally the llama hold the key to COVID-19? The immune system of the black-coated animal, who lives on a farm in Massachusetts, was coaxed into producing “nanobodies” — smaller cousins of antibodies — that neutralized the coronavirus in laboratory experiments, University of Pitt